Seres therapeutics and nestlÉ health science present results from ecospor iv phase 3 study of vowst™, a microbiota-based oral therapeutic for prevention of recurrence of c. difficile infection, at the digestive disease week (ddw) annual meeting

Cambridge, mass. & hoboken, n.j.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), and nestlÉ health science today announced the presentation of data from the phase 3 open-label ecospor iv study evaluating vowst (fecal microbiota spores, live-brpk) – the first and only u.s. food and drug administration (fda)-approved orally administered microbiota-based therapeutic for the prevention of recurrence in adults with recurrent c. difficile (rcdi) following antibacterial treatment. vowst is.
MCRB Ratings Summary
MCRB Quant Ranking